Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cencora ( (COR) ) just unveiled an update.
On February 5, 2025, Cencora reported a revenue increase of 12.8% year-over-year to $81.5 billion for the first quarter of fiscal 2025. The adjusted diluted earnings per share rose by 13.7% to $3.73. The company has raised its adjusted diluted EPS guidance range for fiscal 2025 and emphasized its strategic focus on specialty services following the acquisition of Retina Consultants of America. Despite a decrease in GAAP diluted EPS and operating income, Cencora highlighted its customer-centric approach and execution of its pharmaceutical strategy as key drivers for maintaining its market leadership.
More about Cencora
Cencora, Inc., a leading healthcare services provider, focuses on advancing its core capabilities and enhancing its value proposition through differentiated services and solutions. The company is committed to a pharmaceutical-centric strategy and is known for its leadership in specialty services, as demonstrated by its acquisition of Retina Consultants of America.
YTD Price Performance: 11.94%
Average Trading Volume: 1,243,458
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $49.32B
For a thorough assessment of COR stock, go to TipRanks’ Stock Analysis page.
